Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations

Yuka Ohata, Yoshiko Tomita, Mitsunobu Nakayama, Tsuneo Kozuki, Keisuke Sunakawa, Yusuke Tanigawara

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

A population pharmacokinetic (PK) model for meropenem in Japanese pediatric patients with various infectious diseases was developed based on 116 plasma concentrations from 50 pediatric patients. The population PK parameters developed in this analysis are useful for calculation of the percent time above minimum inhibitory concentration (%T>MIC) and for optimal dosing of meropenem in pediatric patients. After dosing at 20mg/kg t.i.d. by 0.5-h infusion (approved standard dose for pediatric patients in Japan), the target value of 50%T>MIC was achieved, indicating that 20mg/kg t.i.d. by 0.5-h infusion is effective for susceptible bacteria. In contrast, for bacteria with higher MICs such as Pseudomonas aeruginosa (MIC ≥ 2 μg/mL), the probability of target attainment of 50%T>MIC was 60.7% at a dose of 40mg/kg t.i.d. by 0.5-h infusion (highest dose approved for pediatric patients in Japan). The simulations described in this article indicated that 40 mg/kg t.i.d. with a longer infusion duration (e.g., 4 h) is more effective against bacteria with a MIC higher than 2 μg/mL. The predicted probability of target attainment for 50%T>MIC (97.0%) was well correlated not only to the microbiological efficacy rate (97.0%) but also to the clinical efficacy rate (95.9%) in the present phase 3 study.

Original languageEnglish
Pages (from-to)523-531
Number of pages9
JournalDrug Metabolism And Pharmacokinetics
Volume26
Issue number5
DOIs
Publication statusPublished - 2011 Jan 1

Keywords

  • %T>MIC
  • Meropenem
  • Monte Carlo simulation
  • PK/PD
  • Pediatrics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations'. Together they form a unique fingerprint.

Cite this